What Corstasis Therapeutics does

Corstasis Therapeutics is a commercial-stage biopharmaceutical company headquartered in Henderson, Nevada, that develops outpatient therapeutic options for fluid overload associated with congestive heart failure (CHF), hepatic disease, and renal disease. Its core asset, Enbumyst (bumetanide nasal spray) 0.5 mg, is the first and only FDA-approved nasal spray loop diuretic, approved in September 2025 for treating edema in CHF, liver, and kidney disease patients. The company also maintains a development pipeline that includes RSQ-786 (a subcutaneous diuretic delivered via a multidose pen injector), RSQ-789 (a subcutaneous diuretic delivered via a smart infusion system), and RSQ-781 (a veterinary diuretic spray), all investigational.

The company's underlying technology is a nasal drug delivery platform for loop diuretics that exploits the nasal capillary network to bypass first-pass hepatic metabolism, delivering bumetanide directly to systemic circulation to address an absorption limitation of oral loop diuretics in certain patient populations. Corstasis generates revenue through prescription product sales of Enbumyst to healthcare providers and outpatient cardiology networks, with a go-to-market model anchored on channel partnerships with US Heart & Vascular, FillPoint Health, and Cardiovascular Logistics in the United States.

The business model combines direct prescription drug sales with a deal structure inherited from the Esperion Therapeutics acquisition completed in April 2026, which provided $75 million upfront, up to $180 million in milestone payments, and low double-digit royalties to former Corstasis shareholders on worldwide Enbumyst sales. Prior to the acquisition, Corstasis had been funded by an undisclosed strategic investment from Triton Funds in June 2023 and operated with a 1-10 employee structure. The Esperion acquisition expands the commercial reach through the acquirer's established cardiovascular field-sales infrastructure for distribution to cardiology practices, hospitals, and outpatient networks across the United States.

Name

Corstasis Therapeutics

Legal name

Corstasis Therapeutics Inc.

Website

https://corstasis.com

Company type

Private

Founded year

2023

Operating status

Acquired

Headcount range

1–10 employees

Short description

Corstasis Therapeutics is a commercial-stage biopharmaceutical company that developed Enbumyst, the first FDA-approved nasal spray loop diuretic for edema in congestive heart failure, hepatic, and renal disease patients. It was acquired by Esperion Therapeutics in April 2026.

Ownership category

akta.pro rank

Product category

Cardiovascular Pharmaceuticals

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

Keywords

• Nasal drug delivery
• Loop diuretic therapy
• Heart failure treatment
• Biopharmaceutical products
• Outpatient therapeutics

Headquarters

HQ city

Henderson

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Enbumyst product sales: Corstasis commercializes Enbumyst (bumetanide nasal spray), the first FDA-approved nasal spray loop diuretic, generating revenue through prescription drug sales to healthcare providers and outpatient care networks. Following the acquisition by Esperion Therapeutics, Corstasis shareholders receive low double-digit royalties on worldwide sales plus potential milestone payments.
2. Milestone payments from acquisition: Under the Esperion acquisition agreement, Corstasis shareholders receive up to $180 million in additional milestone payments tied to regulatory and commercial achievements, on top of the $75 million upfront cash payment.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Corstasis Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes nasal and subcutaneous formulations of loop diuretics. Its core offering is Enbumyst (bumetanide nasal spray) 0.5 mg, the first FDA-approved nasal spray loop diuretic for outpatient treatment of fluid overload associated with congestive heart failure, liver disease, and kidney disease. The company also has a pipeline of investigational subcutaneous and veterinary diuretic delivery programs.

Product overview

Corstasis Therapeutics is a commercial-stage biopharmaceutical company focused on developing innovative outpatient therapeutic options for patients with fluid overload associated with congestive heart failure (CHF), liver, and kidney disease. The company's core product is Enbumyst (bumetanide nasal spray), an FDA-approved nasal spray loop diuretic that provides self-administered outpatient treatment. Beyond Enbumyst, the company has a pipeline of investigational diuretic products including RSQ-786 (subcutaneous multidose pen injector), RSQ-789 (subcutaneous smart infusion system), and RSQ-781 (veterinary diuretic spray), representing alternative delivery methods for diuretic therapy. The company was acquired by Esperion Therapeutics in 2026 for $75 million upfront plus milestones.

Differentiator

Problem solved

Functional benefit

Brands

• Enbumyst: ENBUMYST (bumetanide nasal spray) - the first and only FDA-approved nasal spray loop diuretic for treating edema associated with congestive heart failure, liver disease, and kidney disease. Approved by FDA in September 2025.

Products and services

• Enbumyst (bumetanide nasal spray) 0.5 mg
• RSQ-786 (Subcutaneous Diuretic Multidose Pen Injector)
• RSQ-789 (Subcutaneous Diuretic Smart Infusion System)
• RSQ-781 (Veterinary Diuretic Spray)

Quantifiable outcome

• Enbumyst demonstrated bioequivalence to oral and IV forms of bumetanide in clinical trials, proving efficacy in patients without heart failure or heart failure risk factors.
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered major.

• US Heart & VascularmajorChannel Partner/ Reseller/ Distributor · 18 December 2025US Heart & Vascular announced a strategic collaboration with FillPoint Health and Corstasis Therapeutics to improve access and adherence to Enbumyst across its national network in the United States. The collaboration aimed to streamline delivery, enhance patient outcomes, and expand access to non-oral diuretic therapy, with nationwide rollout planned by 2026.
• FillPoint HealthmajorChannel Partner/ Reseller/ Distributor · 18 December 2025FillPoint Health partnered with US Heart & Vascular and Corstasis Therapeutics to improve access and adherence to Enbumyst across US Heart & Vascular's national network. The collaboration targeted outpatient heart failure care with nationwide rollout planned by 2026.
• Cardiovascular LogisticsmajorChannel Partner/ Reseller/ Distributor · 26 November 2025Corstasis Therapeutics and Cardiovascular Logistics partnered to support clinical adoption of ENBUMYST for outpatient heart failure care following FDA approval. This partnership was among the first to operationalize nasal-delivered loop diuretics in outpatient cardiology networks in the United States.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• American Regent: American Regent manufactures and distributes injectable bumetanide and other parenteral loop diuretics in the U.S. It addresses the same CHF and edema patient population as Corstasis, currently via IV/IM administration that Enbumyst aims to displace for outpatient use.
• Pfizer Inc. Pfizer (including its Hospira injectables business) supplies generic parenteral furosemide, the dominant IV loop diuretic in the U.S. Its broad cardiovascular portfolio and established hospital channel make it a relevant incumbent comparable for an outpatient loop diuretic.
• Eli Lilly and Company: Eli Lilly (jointly with Boehringer Ingelheim) markets empagliflozin (Jardiance), which carries HFpEF and HFrEF indications. Lilly's large cardiovascular commercial infrastructure is a relevant benchmark for Enbumyst's go-to-market scale and outpatient-channel reach.
• Esperion Therapeutics: Esperion Therapeutics acquired Corstasis in 2026 and now commercializes Enbumyst through its cardiovascular commercial infrastructure (NEXLETOL/NEXLIZET bempedoic acid franchise). It is comparable as a cardiology-focused pharma company operating around Enbumyst as an outpatient CHF asset.

Emerging players

• Cytokinetics, Inc. Cytokinetics is developing cardiac myosin modulators (e.g., omecamtiv mecarbil and aficamten) for heart failure. Its focus on novel mechanisms targeting the same CHF population makes it a comparable emerging cardiology franchise.
• Impel Pharmaceuticals: Impel Pharmaceuticals is a developer of nasal drug delivery platforms (e.g., Trudhesa for migraine). Its technology overlap with Corstasis' nasal delivery platform makes it a strategically comparable emerging player, even though its therapeutic focus differs.
• Windtree Therapeutics: Windtree Therapeutics is developing istaroxime and other cardiovascular assets for acute heart failure. Its emerging-player status in the same heart failure drug development category, with novel mechanisms and small headcount, makes it a relevant comparable for early-stage CHF innovators.
• BioCardia, Inc. BioCardia is developing cardiac delivery platforms (including intramyocardial and subcutaneous delivery systems). Its focus on alternative drug-delivery routes for cardiovascular therapy is comparable to Corstasis' pipeline posture around RSQ-786 and RSQ-789 subcutaneous diuretics.
• OptiNose, Inc. OptiNose develops and commercializes drug-device combinations based on its proprietary nasal delivery technology (e.g., Xhance). It is a directly comparable technology platform for nasal drug delivery that informs device-formulation strategy for Enbumyst-style products.

Direct peers

• scPharmaceuticals Inc. scPharmaceuticals developed Furoscix, a subcutaneous furosemide on-body infusor for outpatient heart failure decongestion. It is the most direct competitive comparable to Corstasis' outpatient diuretic strategy and serves the same CHF fluid-overload patient population through a similar self-administered approach.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corstasis Therapeutics